TXA in Polytrauma (2022-2024)

  • Haemorrhage is a leading cause of early and preventable deaths among injured persons. In addition, haemorrhagic shock with traumatic brain injury (i.e., polytrauma) increases mortality risk.
  • The overarching purpose of this study is to assess the morbidity and mortality of polytrauma patients attributable to tranexamic acid (TXA, or Cyclokapron).
  • We will compare the outcomes of patients administered TXA with comparably injured patients who do not receive TXA. Further, we propose to conduct this research in a ‘real-world’ prolonged care setting with a high incidence of severe polytrauma resulting in head and torso haemorrhage. The study in a ‘real-world’ population may help to overcome several of the generalizability limitations of prior clinical trials.
  • Our primary hypothesis is that we will find a 10% lower 7-day mortality rate54 among patients who receive TXA compared to no TXA. We also expect more improved morbidity (i.e., Multiple Organ Failure scores and Glasgow Outcomes Scale scores) among those who receive TXA compared with those who do not receive TXA.
Scroll to Top